Navigation Links
Sales of Etimicin Sulfate to Expand Nationwide as Government Restriction is Lifted

SANTA MONICA, Calif., Oct. 9 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA), one of mainland China's leading pharmaceutical companies, today announced that the Chinese government has loosened national restrictions for the sale of Etimicin sulfate throughout China. Aida expects the sales of the Company's main revenue-generating product to increase noticeably as sales efforts are pursued nationwide without restriction.

The Ministry of Labor and Social Security eliminated restrictions on Etimicin, which is in the aminoglycoside antibiotic family. Aminoglycoside antibiotis were previously thought to be potentially unsafe for treating patients with a history of kidney disease. Although Etimicin had been clinically established to be safe and effective for people with such issues, it was not until now that the restrictions have been lifted.

Jin Biao, Chairman and CEO of Aida Pharmaceuticals, noted, "This is strong substantiation by the appropriate governmental regulatory body that the safeness of Etimicin has been universally and officially recognized. We are definitely pleased at this acceptance of the outstanding characteristic of low toxicity in this new generation of aminoglycoside antibiotics. We believe that this will allow us to promote the sales of Etimicin and broaden our customer base."

For more information about the lifting of the restriction for this particular type of drug please visit:

About Etimicin Sulfate

Etimicin Sulfate is a new generation of the aminoglycoside family of antibiotics. Developed by Aida and its research partners, it is the first antibiotic developed in China. Aida has the exclusive right to the production and marketing of this powder and infusion type and is protected by patent through 2013. Etimicin sulfate is a semi-synthesized soluble antibiotic.

Researchers and doctors who performed the clinical tests believe that the product is a new generation of aminoglycoside antibiotics with high efficiency, safety and effectiveness to a broad spectrum of strains. Etimicin sulfate is suitable for the treatment of various inflammations, such as respiratory infections, kidney and urinogenital infections, soft skin tissue infection, as well as trauma and operation preventative uses.

About Aida

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices.

SOURCE Aida Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Jellyfish partners for sales tracking technology
2. Doyle wants sales tax applied to digital downloads
3. Mortgagebot builds online sales even as housing declines
4. Third Wave reports another loss, stronger sales
5. Johnson Controls reports record quarterly sales
6. Can sales outsourcing grow Wisconsin biotechs?
7. Sonic Foundry reports quarterly loss, higher Mediasite sales
8. My-oh, its BIO! Where sales hype and science collide
9. Third Wave shuffles finance, sales management
10. Johnson Controls sales up, profits down
11. Turning ads into sales: Context is king
Post Your Comments:
(Date:12/1/2015)... Vancouver , booth ... features Owen Mumford,s unique Comfort Zone Technology®. --> ... is a touch activated lancet that features Owen Mumford,s ... a leading medical device manufacturer, today unveils a new ... in the US before expanding out to other markets. ...
(Date:12/1/2015)... , Dec. 1, 2015 Oxford Finance LLC ... to life sciences and healthcare services companies, today announced ... loan with MDRejuvena, Inc. ("the Company"). Proceeds from the ... development of the Company,s Rejuvaphyl™ and daily skincare products. ... is the MDRejuvena brand of high potency skincare products ...
(Date:12/1/2015)... ... December 01, 2015 , ... RURO, ... best selling system laboratory animal colony management software solution, ezColony®, is now available ... on-site IT resources., , Many organizations are moving to ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... meeting this month and Dr. J. Kyle Mathews will join fellow ... the new single site hysterectomy. , An experienced urogynecologist, founder of Plano Urogynecology ...
Breaking Biology Technology:
(Date:11/20/2015)... -- NXTD ) ("NXT-ID" or the "Company"), ... commerce market and creator of the Wocket® smart wallet, ... interviewed on The RedChip Money Report television ... Bloomberg Europe , Bloomberg Asia, Bloomberg Australia, and ... ) ("NXT-ID" or the "Company"), a biometric authentication company ...
(Date:11/18/2015)... , November 18, 2015 ... has published a new market report titled  Gesture Recognition ... and Forecast, 2015 - 2021. According to the report, the global ... and is anticipated to reach US$29.1 bn by 2021, ... North America dominated the ...
(Date:11/17/2015)... EASTON, Mass. , Nov. 17, 2015 ... a leader in the development and sale of broadly ... the worldwide life sciences industry, today announced it has ... of its $5 million Private Placement (the "Offering"), increasing ... to $4,025,000.  One or more additional closings are expected ...
Breaking Biology News(10 mins):